Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Catheter Precision, Inc. on May 30, 2025. The filing addresses Item 8.01 (Other Events) to provide dilution information for incorporation into outstanding registration statements. The company is incorporated in Delaware and trades on the NYSE American under the symbol VTAK.
Key Financial Metrics
The filing focuses on net tangible book value rather than operational revenue or profit metrics. As of March 31, 2025, the company reported a negative net tangible book value of $(15.8) million, or $(1.71) per share, based on 9,268,632 shares outstanding. Following the issuance of 1,748,666 shares in April 2025, the pro forma net tangible book value remained negative at $(15.84) million, or $(1.44) per share, based on 11,017,298 adjusted shares.
The filing illustrates a hypothetical "at the market" offering scenario assuming the sale of 4,333,333 shares at $0.30 per share, generating estimated net proceeds of $1.2 million. Under this scenario, the pro forma as adjusted net tangible book value would be $(14.6) million, or $(0.95) per share.
Material Changes and Dilution Analysis
The primary material change disclosed is the significant dilution impact on new investors versus existing shareholders in a hypothetical equity offering:
- Existing Shareholders: Would see an immediate increase in net tangible book value of $0.49 per share.
- New Investors: Would face an immediate and substantial dilution of $(1.25) per share, calculated as the difference between the assumed offering price of $0.30 and the pro forma as adjusted net tangible book value of $(0.95).
The filing notes that actual dilution will vary based on the final offering price and volume. Sensitivity analysis indicates that a $0.10 increase in the offering price would increase dilution to new investors to $(1.43) per share, while a $0.10 decrease would reduce dilution to $(1.04) per share.
Outlook, Risks, and Contingencies
Management highlights several risks regarding future capitalization and dilution:
- Outstanding Equity Instruments: Significant shares are reserved for future issuance, including 17,385,613 shares under outstanding warrants (weighted average exercise price $2.20), 1,641,184 shares under equity incentive options, and 525,000 shares under non-plan options.
- Future Capital Raises: The company may raise additional capital through equity or convertible debt, which could result in further dilution to stockholders.
- Variable Offering Terms: The dilution figures provided are illustrative and assume specific share counts and prices; actual terms may differ.
Key Facts for Investor Verification
- Verify the current market price of VTAK stock relative to the assumed $0.30 offering price used in the dilution model.
- Confirm the total number of outstanding warrants (17.4 million) and their weighted average exercise price ($2.20) to assess potential future dilution.
- Review the company's cash position and burn rate, as the filing indicates a negative net tangible book value of approximately $(15.8) million.
- Monitor the actual execution of the "at the market" offering to determine if the hypothetical 4.3 million share sale volume is achieved.